Razelle Kurzrock, MD
Razelle Kurzrock, MD
Distinguished Professor of Medicine, UC San Diego School of Medicine
Verified email at ucsd.edu
Title
Cited by
Cited by
Year
The biology of chronic myeloid leukemia
S Faderl, M Talpaz, Z Estrov, S O'Brien, R Kurzrock, HM Kantarjian
New England Journal of Medicine 341 (3), 164-172, 1999
16201999
PD-L1 expression as a predictive biomarker in cancer immunotherapy
SP Patel, R Kurzrock
Molecular cancer therapeutics 14 (4), 847-856, 2015
13702015
Phase II trial of curcumin in patients with advanced pancreatic cancer
N Dhillon, BB Aggarwal, RA Newman, RA Wolff, AB Kunnumakkara, ...
Clinical cancer research 14 (14), 4491-4499, 2008
13132008
Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers
AM Goodman, S Kato, L Bazhenova, SP Patel, GM Frampton, V Miller, ...
Molecular cancer therapeutics 16 (11), 2598-2608, 2017
12212017
The molecular genetics of Philadelphia chromosome–positive leukemias
R Kurzrock, JU Gutterman, M Talpaz
New England Journal of Medicine 319 (15), 990-998, 1988
10651988
Epstein-Barr virus and cancer
MP Thompson, R Kurzrock
Clinical cancer research 10 (3), 803-821, 2004
8952004
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
GS Falchook, GV Long, R Kurzrock, KB Kim, TH Arkenau, MP Brown, ...
The Lancet 379 (9829), 1893-1901, 2012
8772012
Autophagy as a target for anticancer therapy
F Janku, DJ McConkey, DS Hong, R Kurzrock
Nature reviews Clinical oncology 8 (9), 528-539, 2011
7492011
Clinical toxicity of interferons in cancer patients: a review.
JR Quesada, M Talpaz, A Rios, R Kurzrock, JU Gutterman
Journal of Clinical Oncology 4 (2), 234-243, 1986
7381986
Liposome‐encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis
L Li, FS Braiteh, R Kurzrock
Cancer: Interdisciplinary International Journal of the American Cancer …, 2005
7082005
Chronic myelogenous leukemia: a concise update
HM Kantarjian, A Deisseroth, R Kurzrock, Z Estrov, M Talpaz
6081993
Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate
S Kato, A Goodman, V Walavalkar, DA Barkauskas, A Sharabi, ...
Clinical Cancer Research 23 (15), 4242-4250, 2017
5792017
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
R Kurzrock, SI Sherman, DW Ball, AA Forastiere, RB Cohen, R Mehra, ...
Journal of Clinical Oncology 29 (19), 2660, 2011
5382011
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
N Krishnamurthy, R Kurzrock
Cancer treatment reviews 62, 50-60, 2018
5062018
Philadelphia chromosomepositive leukemias: from basic mechanisms to molecular therapeutics
R Kurzrock, HM Kantarjian, BJ Druker, M Talpaz
Annals of internal medicine 138 (10), 819-830, 2003
5062003
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
GS Falchook, KD Lewis, JR Infante, MS Gordon, NJ Vogelzang, ...
The lancet oncology 13 (8), 782-789, 2012
4952012
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients
M Talpaz, H Kantarjian, R Kurzrock, JM Trujillo, JU Gutterman
Annals of internal medicine 114 (7), 532-538, 1991
4861991
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
AM Tsimberidou, NG Iskander, DS Hong, JJ Wheler, GS Falchook, S Fu, ...
Clinical cancer research 18 (22), 6373-6383, 2012
4762012
Sweet's syndrome revisited: a review of disease concepts
PR Cohen, R Kurzrock
International journal of dermatology 42 (10), 761-778, 2003
4672003
Interleukin‐6 and its receptor in cancer: implications for translational therapeutics
DS Hong, LS Angelo, R Kurzrock
Cancer 110 (9), 1911-1928, 2007
4612007
The system can't perform the operation now. Try again later.
Articles 1–20